All News

2023

February

Featured News / Feb 01, 2023

Sandoz Receives Corporate Circle Award from the Crohn’s & Colitis Foundation, Marking the First Time an Emerging Partner Has Received this Honor

Read More
2022

July

Media Release / Jul 25, 2022

Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA

Read More
Media Release / Jul 21, 2022

Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)

Read More

May

Media Release / May 12, 2022

Sandoz launches first generic pirfenidone in US for patients with idiopathic pulmonary fibrosis, growing its respiratory portfolio

Read More

April

Media Release / Apr 13, 2022

Sandoz launches generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension, expanding leading ophthalmic portfolio

Read More

March

Media Release / Mar 21, 2022

Sandoz, Inc. Issues Nationwide Recall of 13 Lots of Orphenadrine Citrate 100 mg Extended Release Tablets Due to Presence of a Nitrosamine Impurity

Read More
2021

December

Media Release / Dec 22, 2021

Sandoz launches authorized generic of Narcan® (naloxone hydrochloride) Nasal Spray 4 mg in US to help reverse opioid overdose, expanding access during surge in overdose deaths

Read More
Media Release / Dec 20, 2021

Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA

Read More
Media Release / Dec 16, 2021

Sandoz, Inc. Issues Nationwide Recall of One Lot of Enoxaparin Sodium Injection, USP 40mg/0.4 mL Due to Temperature Excursion during Shipping

Read More

October

Media Release / Oct 01, 2021

Sandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic Drugs

Read More